

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors and/or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.*



**CStone Pharmaceuticals**

**基石藥業**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2616)**

**VOLUNTARY ANNOUNCEMENT  
FURTHER INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE  
DIRECTOR DR. JIANXIN YANG BY 2,269,500 SHARES,  
WITH ACCUMULATED PURCHASE TOTALLING 9,799,000 SHARES**

This announcement is made by CStone Pharmaceuticals (the “**Company**” or “**CStone**” and together with its subsidiaries, the “**Group**”) on a voluntary basis to inform its shareholders and potential investors in relation to the increase in shareholding in the Company (the “**Shares**”) by Dr. Jianxin Yang (“**Dr. Yang**”), the chief executive officer (the “**CEO**”), president of research and development and an executive director of the Company.

The Company was informed by Dr. Yang that he has purchased a total of 2,269,500 Shares in the open market with his own funds on June 5 to 7, June 17 to 21 and October 18, 2024 (the “**Share Purchases**”), of which 1,383,000 Shares purchased in June 2024 with purchase price per Share ranging from HKD1.06 to HKD1.26, and 886,500 Shares purchased on October 18, 2024 with purchase price per Share ranging from HKD1.63 to HKD1.79. Since assuming the role as CEO in August 2022, Dr. Yang has purchased a total of 9,799,000 Shares in the open market with purchase price per Share ranging from HKD 0.82 to HKD 4.60. Following the Share Purchases, Dr. Yang’s total shareholding interest in the Company was approximately 5.44% of the total issued share capital of the Company as at the date of this announcement.

Dr. Yang informed the Company that he is confident with the Company’s outlook, and the increase in his shareholding in the Company represents his belief in the Company’s ability to maintain steady operations and to achieve rapid growth in a complex and volatile market environment, and the Share Purchases demonstrates his unfailing support towards the growth and development of the Company. Dr. Yang does not rule out the possibility of further increasing his shareholding in the Company as and when appropriate.

The board of directors of the Company (the “**Board**”) is of the view that the increase in shareholding of the

Company by its CEO, president of research and development and executive director signifies Dr. Yang's long-term commitment to, and confidence towards, the future business prospects of the Company.

## **About CStone**

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies. Dedicated to addressing patients' unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 15 new drug applications (NDAs) covering 9 indications. The Company's pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multi-specific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.

For more information about CStone, please visit: [www.cstonepharma.com](http://www.cstonepharma.com).

By Order of the Board  
**CStone Pharmaceuticals**  
**Dr. Wei Li**  
Chairman

Suzhou, the People's Republic of China, October 23, 2024

*As at the date of this announcement, the board of directors of the Company comprises Dr. Wei Li as Chairman and non-executive director, Dr. Jianxin Yang as executive director, Mr. Kenneth Walton Hitchner III, Mr. Xianghong Lin and Mr. Edward Hu as non-executive directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive directors.*